to beachcomber what do you think of this study?:
MMR Vaccine Not Linked to Autism in Virologic Case Control Study CME/CE
News Author: Marlene Busko
CME Author: Laurie Barclay, MD
Disclosures
Release Date: February 11, 2008;
Authors and Disclosures
Marlene Busko
Disclosure: Marlene Busko has disclosed no relevant financial relationships.
Laurie Barclay, MD
Disclosure: Laurie Barclay, MD, has disclosed no relevant financial relationships.
Brande Nicole Martin
Disclosure: Brande Nicole Martin has disclosed no relevant financial information.
February 11, 2008 ? No differences in measles virus or measles antibody concentrations were detected between children with autism spectrum disorders (ASD) and controls, whether they had received 1 or 2 measles, mumps, and rubella (MMR) vaccinations, in a study from the United Kingdom.
The investigators did not find any evidence of a persisting immunologic response in children with ASD, whether these children also had regression in words, social skills, or behavior, and they did not find increased enterocolitis (bowel disorders) in children with ASD and regression.
The study, led by Gillian Baird, PhD, at Guy's Hospital, in London, England, is reported in the February 5 Online First issue of the Archives of Disease in Childhood.
"This is one of three virological case-control studies [and the largest of the three] that have failed to demonstrate any association between measles vaccination and ASD, using well-validated techniques," the group writes.
Are Vaccines to Blame?
A 1998 report of a study in 12 children suggested that MMR vaccination might be linked to the development of ASD, and a subsequent study postulated that the vaccine might be associated with enterocolitis, the group writes. Subsequent epidemiologic studies, however, discredited this research and failed to demonstrate an association between MMR vaccination and ASD. Despite these subsequent findings, parental concerns have led to a decrease in MMR vaccinations in the United Kingdom from 92% to 80%.
The investigators of the current study aimed to test the hypothesis that measles vaccination was involved in the pathogenesis of ASD, by looking for raised levels of the measles virus or measles antibodies in children with ASD who had been vaccinated with the MMR vaccine vs control groups of vaccinated children.
The subjects were derived from a community-based sample of vaccinated children, aged 10 to 12 years, from a population of almost 57,000 children born between 1990 and 1991 in southern England.
The study sample was made up of 98 children with ASD and 2 control groups: 52 children with special educational needs but no ASD, and 90 typically developing children.
Blood tests were performed to detect the presence of the measles virus and to test for measles antibody levels.
No difference was found between cases and controls for measles antibody response or for enterocolitis, regardless of whether the children showed regression.
The children with ASD or with special educational needs were, however, less likely than the typically developing children to receive the second MMR vaccination (MMR2).
Need to Look Beyond MMR Vaccine
This case-control study used a complementary approach to the epidemiologic studies that demonstrated that the rates of autism prevalence did not decrease after the removal of the vaccine preservative thimerosal, Eric Hollander, MD, from Mount Sinai School of Medicine in New York, who was not involved in this study, told Medscape Psychiatry.
"From this study, it's clear that persistence of the measles virus or the antibody response doesn't occur in patients with autism compared to typically developing individuals or to children in special education, irrespective of the number of doses of the vaccine," he noted.
Research shows that very early childhood experience or environmental factors can play a role in modifying the expression of certain genes and the development of autism, which suggests that it is important to look for environmental factors, he added.
Focusing on the MMR vaccine or mercury as potential environmental factors is not warranted, however, given the negative research findings. "I would say at this point, it would be much more fruitful to invest resources...into looking at other potential environmental factors that could play a role," Dr. Hollander believes.
"Autism places more stress on parents than any other illness," he added, "and it's not unusual for families to seek what may have caused this particular problem in a child that seemed to be developing normally and then all of a sudden regressed, and sometimes people may seize on things that seem to co-occur at the same time.
"It's important to move past anecdotal observations and do more systematic studies to either prove or disprove certain [them], and I also think it's important...to be able to incorporate new data and modify hypotheses to most effectively find out what the real underlying causes of autism are, to have major breakthroughs," he concluded.
The study was funded by the Department of Health, the Wellcome Trust, the National Alliance for Autism Research, and Remedi. Two of the study authors have given unpaid advice to lawyers in MMR and MR litigation. Two other study authors have acted as expert witnesses for the diagnosis of autism and in the matter of MMR/MR vaccine litigation. One other study author has received royalties from diagnostic assessments used in the study. The remaining study authors have disclosed no relevant financial relationships.
Arch Dis Child. Published online February 5, 2008.
Clinical Context
The estimated prevalence of ASD based on recent studies ranges between 6 and 12 per 1000, depending on the strictness of criteria used for diagnosis. A 1998 report of an uncontrolled case series of 12 children suggested a link between MMR vaccination and subsequent development of ASD, and a larger case series described "autism enterocolitis" thought to be associated with MMR vaccination and regression in autism.
However, several epidemiologic studies later found no association between MMR vaccination and ASD. The present analysis used a new, geographically defined study of ASD prevalence (Special Needs and Autism Project [SNAP]) to examine the hypothesis that the measles vaccine was involved in the pathogenesis of ASD.
Study Highlights
The goal of this case-control, community-based study was to test the hypothesis that measles vaccination was involved in the pathogenesis of ASD.
Evidence for that hypothesis was defined a priori as signs of a persistent measles infection or abnormally persistent immune response shown by circulating measles virus or raised antibody titers in MMR-vaccinated children with ASD and with a history of regression vs controls.
The study sample consisted of a community sample of 98 vaccinated children aged 10 to 12 years in the United Kingdom with ASD and 2 control groups of similar age: 1 group of 52 children with special educational needs but without ASD and 1 group of 90 children with typical development.
Participants underwent testing for measles virus and serum antibody response to measles.
Cases and controls did not differ in measles antibody response or in measles virus, whether the children had received the first, second, or both MMR vaccinations.
There was no dose-response relationship between autism symptoms and antibody concentrations.
Measles virus nucleic acid was amplified by reverse transcriptase?polymerase chain reaction in peripheral blood mononuclear cells from 1 patient with autism and from 2 children with typical development.
Response to measles virus or to the measles component of the MMR in children with ASD, with or without regression, did not seem to differ from that in children in the control groups who had either 1 or 2 doses of MMR.
Clinical symptoms of possible enterocolitis occurred in none of the cases and in only 1 child from the combined control group.
Based on these findings, the investigators concluded that there was no association demonstrated between measles vaccination and ASD.
Limitations of the study include subjects in the typical development group not randomly selected from the whole population; parents being informed that the study was about MMR vaccination may have led to response bias; satisfactory blood samples not obtained in 100 children, both ASD cases and control group with special educational needs; and lack of gut mucosal samples for ethical reasons.
After diagnosis of a developmental problem, children were less likely to receive the MMR2, which the investigators suggested may reflect parental concern about vaccination after a diagnosis of a developmental abnormality.
Both ASD cases and the control group with special educational needs had lower uptake of MMR2 and, hence, less exposure to the measles virus.
Only 29% (20/70) of children diagnosed with ASD received MMR2 vs 50% (14/28) of those who were not diagnosed with ASD.
Pearls for Practice
The investigators concluded that there was no association demonstrated between measles vaccination and subsequent development of ASD. Cases and controls did not differ in measles antibody response or in measles virus, there was no dose-response relationship between autism symptoms and antibody concentrations, and clinical symptoms of possible enterocolitis occurred in none of the cases.
After diagnosis of a developmental problem, children were less likely to receive the MMR2, which the investigators suggested may reflect parental concern about vaccination after a diagnosis of a developmental abnormality. Only 29% of children diagnosed with ASD received MMR2 vs 50% of those who were not diagnosed with ASD.